Two-year outcomes of the primary latarjet procedure: a nationwide analysis of 2258 patients
Archives of Orthopaedic and Trauma Surgery · 2025
DOI: 10.1007/s00402-025-06142-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Orthopaedic and Trauma Surgery, 2025. Verfasst von Robert J Burkhart und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics, University Hospitals of Cleveland, Cleveland, USA. rjb246@case.edu. Hauptthemen laut MEDLINE: Shoulder Joint, Joint Instability, Shoulder Dislocation. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: The Latarjet procedure effectively restores glenohumeral stability, particularly in patients with anterior shoulder instability and glenoid bone loss. However, existing outcome data are primarily derived from single-center studies. Therefore, the purpose of this study was to evaluate the short- and long-term outcomes of the Latarjet procedure in a nationwide population. METHODS: TriNetX, a global federated research network, was retrospectively queried to identify patients undergoing primary Latarjet. Patients that underwent prior capsulorrhaphy were excluded. The patient cohorts were evaluated for demographic factors, including age, sex, race, and ethnicity. Postoperative outcomes were assessed in the 30, 90, 180 days, and two years. Subgroup analysis was performed to evaluate the impact of sex on complication rates and healthcare utilization. RESULTS: A total of 2,258 patients met the inclusion criteria. The cohort was predominately male (81%), with a mean age of 34 ± 12 years and a mean BMI of 26 ± 6 kg/m². Over the short and mid-term follow-up periods, complications such as SSI, DVT, sepsis, hematoma, and myocardial infarction remained uncommon (less than 2%). By two years, the rate of emergency department (ED) visits nearly doubled to 14%, yet serious adverse events and revision surgeries (3.6%) remained rare. Men and women exhibited similar overall complication profiles, with no significant sex-based differences in most outcomes. However, women were more likely than men to utilize the ED (23% vs. 15%; OR, 0.56; 95% CI, 0.454-0.869; p = 0.0043). CONCLUSION: The Latarjet procedure demonstrated low rats of both short- and long-term complications. While ED visits and complications such as shoulder dislocation increased over time, overall postoperative risk remained low. Complications were similar between men and women at two-year follow-up, with both groups experiencing low rates of serious adverse events. However, women's higher rates of emergency department visits warrant further investigation. These findings support the long-term safety and efficacy of the Latarjet procedure in a large, nationally representative cohort. LEVEL OF EVIDENCE: Level III.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Orthopaedics, University Hospitals of Cleveland, Cleveland, USA. rjb246@case.edu.
- Department of Orthopaedics, University Hospitals of Cleveland, Cleveland, USA.
Zitieren
APA
J Burkhart, R., Abid, R., E Guven, A., J Moyal, A., M Adelstein, J., M Fortier, L., E Voos, J., G Calcei, J., & J Salata, M. (2025). Two-year outcomes of the primary latarjet procedure: a nationwide analysis of 2258 patients. Archives of Orthopaedic and Trauma Surgery. https://doi.org/10.1007/s00402-025-06142-x
Vancouver
J Burkhart R, Abid R, E Guven A, J Moyal A, M Adelstein J, M Fortier L, et al. Two-year outcomes of the primary latarjet procedure: a nationwide analysis of 2258 patients. Archives of Orthopaedic and Trauma Surgery. 2025. doi:10.1007/s00402-025-06142-x
BibTeX
@article{JBurkhart2025,
author = {J Burkhart, Robert and Abid, Rayyan and E Guven, Ali and J Moyal, Andrew and M Adelstein, Jeremy and M Fortier, Luc and E Voos, James and G Calcei, Jacob and J Salata, Michael},
title = {Two-year outcomes of the primary latarjet procedure: a nationwide analysis of 2258 patients},
journal = {Archives of Orthopaedic and Trauma Surgery},
year = {2025},
doi = {10.1007/s00402-025-06142-x}
}
EUVIMED